Addressing Unmet Need in

Neuropathic Corneal Pain

Urcosimod (formerly called OK-101) Drug Candidate

  • Urcosimod is a novel class of chemerin (ChemR23 or CMKLR1) receptor agonist that produces an anti-inflammatory and reduction in neuropathic pain.
  • The chemerin receptor is a G protein-coupled receptor (GPCR) found on select immune, epithelial, and dorsal root ganglion/spinal cord neuronal cells.
  • Activation of chemerin receptor has been shown to modulate the resolution of inflammation and neuropathic pain.
  • Urcosimod can potentially benefit patients suffering from ocular pain and ocular inflammation.

Neuropathic Corneal Pain (NCP)

  • A chronic pain condition due to nerve damage or dysfunction in the corneal region.
  • Severe eye pain, burning, foreign body sensation and light sensitivity (photophobia)
  • Can result from trauma, surgery (e.g., refractive surgery), infections, or conditions like dry eye disease that affect corneal nerves.
  • The pain is due to abnormal signalling in the corneal nerves, which may become sensitized or dysfunctional, leading to persistent pain.
  • No FDA approved treatment.
  • OKYO is the first company to receive an investigational new drug (IND) application clearance by FDA to clinically evaluate a drug specifically to treat NCP

Dry Eye

  • Dry Eye affects over 35% of the population aged 50+, with women representing approximately two-thirds of those affected
  • Worldwide, ~700 M patients suffer from dry eye disease
  • Several side effects and modest efficacy of currently available drugs demand new therapies to treat dry eye disease
  • Huge potential for new drugs for a $5 Billion dry eye market